| 1 |
33722946 | Is Febuxostat Use Associated With Increased Risk of Cardiovascular Disease Events? The Answer Is Crystal Clear. | 2021 Jul |
1 |
| 2 |
31308200 | Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. | 2019 Sep |
1 |
| 3 |
29642234 | A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. | 2018 May |
1 |
| 4 |
27916277 | The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. | 2017 Apr |
1 |
| 5 |
28957559 | Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. | 2017 Oct 1 |
1 |
| 6 |
26771445 | Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. | 2016 Jul |
3 |
| 7 |
26365588 | Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). | 2015 Dec |
1 |